Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Articles

    AstraZeneca plc Could Be Worth 3915p

    | Peter Stephens

    Shareholders in AstraZeneca plc (LON: AZN) could enjoy gains of 18.5% plus a generous dividend. Here’s why…

    Read more »

    Investing Articles

    Why AstraZeneca plc Will Be One Of 2013’s Winners

    | Alan Oscroft

    It's a close run for AstraZeneca plc (LON: AZN) as we approach the end of the year.

    Read more »

    Investing Articles

    A SWOT Analysis Of AstraZeneca Plc And GlaxoSmithKline plc

    | David O'Hara

    What are the key factors affecting the investment proposition at pharmaceutical giants GlaxoSmithKline plc (LON:GSK) and AstraZeneca plc (LON:AZN)?

    Read more »

    Investing Articles

    Angels vs Devils: Should You Invest In AstraZeneca plc?

    | Royston Wild

    Royston Wild considers the pros and cons of investing in AstraZeneca plc (LON: AZN).

    Read more »

    Investing Articles

    This Model Suggests AstraZeneca plc Could Deliver A 6.3% Annual Return

    | Roland Head

    Roland Head explains why AstraZeneca plc (LON:AZN) could deliver a 6.3% annual return over the next few years.

    Read more »

    Company Comment

    AstraZeneca Plc’s Turnaround Story Hasn’t Started Yet

    | Keith Speights

    The turnaround story at AstraZeneca plc (LON:AZN) may require a good deal more time to even begin...

    Read more »

    Investing Videos

    Is AstraZeneca Plc A Good Way To Play Emerging Markets?

    | Owain Bennallack

    VIDEO: One Fool weighs up the emerging-market potential of AstraZeneca plc (LON:AZN).

    Read more »

    Company Comment

    Betting On AstraZeneca plc’s Drug Pipeline

    | Owain Bennallack

    What’s caused £41 billion drugs maker AstraZeneca plc (LON:AZN) to become afflicted by a seemingly interminable wasting disease?

    Read more »

    Investing Videos

    A Closer Look At AstraZeneca plc

    | Jill Ralph

    VIDEO: Two Fools analyse AstraZeneca plc (LON: AZN).

    Read more »

    Company Comment

    Earnings Drop 16% At AstraZeneca Plc

    | Nate Weisshaar

    Investing the future while revenues fall takes its toll on the bottom line at AstraZeneca plc (LON:AZN).

    Read more »

    Investing Articles

    Why You Might Think Of Investing In This FTSE Underdog: AstraZeneca plc

    | Tony Reading

    AstraZeneca plc (LON: AZN) could be a contrarian investment opportunity.

    Read more »

    Investing Articles

    Why Reinvesting Your Dividends Is The Best Decision You’ll Ever Make

    | Rupert Hargreaves

    Dividend reinvestment is a great way to achieve market beating returns without much effort.

    Read more »